683 Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

683 Capital Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-71,500	Closed	-$2.28M	–	143
2024 Q4	$2.28M	Sell	71,500 -128,500	-64%	-$3.86M	0.14%	86
2024 Q3	$5.77M	Hold	200,000	–	–	0.44%	58
2024 Q2	$7.67M	Buy	+200,000	New	+$9.06M	0.58%	47
2024 Q1	–	Sell	-175,000	Closed	-$10.5M	–	148
2023 Q4	$10.5M	Sell	175,000 -401,000	-70%	-$20.3M	0.86%	46
2023 Q3	$21.9M	Buy	576,000 +75,000	+15%	+$3.29M	1.7%	17
2023 Q2	$45.6M	Buy	+501,000	New	+$43.2M	3.28%	6

Other funds holding APLS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

683 Capital Management's APLS Position: Q1 2026 in Review

683 Capital Management reduced its Apellis Pharmaceuticals (APLS) stake by 24% in Q1 2026, selling an estimated $1.72M and leaving 250,000 shares worth $10.1M. The position accounts for 0.52% of the portfolio, ranked #42.

683 Capital Management first reported a position in APLS in Q4 2022 and has held it in 14 quarters since. The position peaked at $12.6M in Q1 2024. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

683 Capital Management held 250,000 shares of Apellis Pharmaceuticals worth $10.1M as of Q1 2026.
683 Capital Management sold 80,000 Apellis Pharmaceuticals shares in Q1 2026, an estimated $1.72M.
Apellis Pharmaceuticals made up 0.52% of 683 Capital Management's portfolio in Q1 2026, its #42 holding.
683 Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
683 Capital Management's Apellis Pharmaceuticals position peaked at $12.6M in Q1 2024.
321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.